FierceBiotech1d
With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
Business Wire1d
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease …
Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...
pharmaphorum1d
MSD preparing to take on Beyfortus with RSV antibody
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
Pharmabiz5h
Merck presents positive results from phase 2b/3 trial of clesrovimab, an investigational RSV preventative monoclonal antibody at IDWeek 2024
Clesrovimab (MK-1654) is an investigational, extended half-life monoclonal antibody (mAb) developed as a passive immunization for the prevention of RSV. Clesrovimab is designed to be administered ...
Daily14h
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
STAT1d
Potential competition for RSV prophylactic Beyfortus
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
WA could be better protected against RSV this winter. Here’s why
Respiratory virus season is underway, but Washington is more prepared than it was last year to protect against some severe ...
RSV, Flu and COVID-19 season is here, so do you need three vaccines?
COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...
Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17)
(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...
cidrap.umn4d
Study: Resistance to antibody rare in RSV breakthrough cases
A new study in The Lancet Infectious Diseases describes the genotypic and phenotypic characteristics of respiratory syncytial ...